Disability Progression in Multiple Sclerosis Patients using Early First-line Treatments

Area of Science:

• Neurology
• Clinical Research
• Treatment Efficacy

Background:

• Therapeutic strategies for relapsing-remitting multiple sclerosis (RRMS) increasingly favor early intervention.
• Assessing the impact of early treatment initiation on long-term disability is crucial for optimizing patient outcomes.

Purpose of the Study:

• To evaluate the effect of early versus later treatment initiation on disability progression in first-line treated RRMS patients.
• To compare the time to reach an irreversible Expanded Disability Status Scale (EDSS) score of 3.0 between early and later treatment groups.

Main Methods:

• A cohort study of 5,279 incident RRMS patients treated with interferon or glatiramer acetate between 1996 and 2012.
• Propensity score weighted Kaplan-Meier methods were used to compare time to EDSS 3.0 between patients treated within 12 months (Early) and those treated later.
• Analysis was stratified by age (≤40 years and >40 years).

Main Results:

• Early treatment initiation (within 12 months of onset) was associated with a longer time to reach EDSS 3.0 compared to later treatment.
• Overall, early treatment extended the time to EDSS 3.0 by an average of 7 months.
• Older patients (>40 years) showed a more pronounced benefit, gaining 14 months in time to EDSS 3.0 with early treatment.

Conclusions:

• Early treatment initiation significantly reduces disability progression in RRMS patients.
• The benefits of early treatment on slowing disability progression are evident across different age groups, including older individuals.